• About
  • Licensing
  • Podcasting
  • Contact

AudioMedica.com

Medical News Interviews

  • Public Health
  • Oncology
  • Cardiovascular
  • General Medicine

Audio Journal of Oncology with Oncology Times News from the 2013 European Cancer Congress

0
  • by alexperjescuadmin
  • in Audio · Oncology
  • — 18 Oct, 2013
Kirstin De Bruijn
Kirstin De Bruijn

IN THIS EDITION:

  • Oral VEGF inhibitor, cediranib, extends life in refractory ovarian cancer
  • Screening has halved colorectal cancer mortality in Europe
  • Diabetes associated with increased risk of incidence and mortality from breast and colorectal cancer
  • HLA predicts which patients with colorectal cancer can live longer when given aspirin
  • Breast screening and treatment budgets: direct link to mortality
  • PSA screening for prostate cancer — not recommended!
  • AMSTERDAM—Important progress in several areas of cancer emerged from the European Cancer Congress. Peter Goodwin and Sarah Maxwell report:
    The oral vascular endothelial growth factor receptor tyrosine kinase inhibitor cediranib extended life in refractory ovarian cancer in first relapse. Professor Jonathan Ledermann MD FRCP, Director of Medical Oncology & UCL Cancer Trials Centre, University College, London, discussed findings from the ICON 6 trial.
    Reassuring findings about the efficacy of screening for colorectal cancer are reported by Philippe Autier, MD, MPH, PhD, Vice President/Population Research at the International Prevention Research Institute in Lyon, France – a halving of colorectal cancer mortality since 1989 in European countries adopting widespread screening.
    Patients with diabetes: at increased risk of developing and dying from breast and colorectal cancer according to research from the Netherlands announced at the Amsterdam congress by Kirstin De Bruijn MD, from Erasmus University Medical Center, in Rotterdam, Netherlands, talking to AudioMedica.com in Amsterdam.
    Leiden University researchers have identified a biomarker capable of predicting which patients with colorectal cancer will have prolonged survival by taking 80 mg of aspirin regularly. Dr Marlies Reimers, MD, from the Department of Surgery at Leiden University Medical Center, Netherlands explains that patients whose tumors express the HLA class one antigen have their mortality halved.
    Researchers from the Breast European Adjuvant Studies Team report that effective treatment and screening for cancers such as breast cancer could be directly linked to the proportion of patients dying within a given period of time after diagnosis. This finding was possible because Europe is — unintentionally — a perfect laboratory for such an investigation, since the different countries have widely varying health-care budgets. There was a linear relationship between healthcare spending and cancer mortality!
    Prostate cancer screening: the ERSPC trial found that in European countries there was a 21 per cent reduction in regions where men are routinely screened using PSA — in contrast to the findings of the American PLCO trial which found no effect. London expert Jack Cuzick said in Amsterdam that the difference was because most Americans get PSA screening anyway, so the study was only a measure of organized versus opportunistic screening. And he highlighted the need to look at the risk-benefit ratio of PSA testing. Until factors can be identified to show which patients benefit, his conclusion was that routine PSA screening should not be recommended!

    Share

You may also like...

  • Audio Journal of Oncology in Advance – May 1st, 2007 – reporting from: American Association for Cancer Research 14-18 April, 2007 Los Angeles Audio Journal of Oncology in Advance – May 1st, 2007 – reporting from: American Association for Cancer Research 14-18 April, 2007 Los Angeles 2 May, 2007
  • Stefan Aibi and Irene Wapnir Local or regional breast cancer recurrences mandate adjuvant chemotherapy 11 Dec, 2012
  • PD-L1 Immunotherapy Delayed Triple Negative Breast Cancer Progression PD-L1 Immunotherapy Delayed Triple Negative Breast Cancer Progression 31 Oct, 2018
  • Audio Journal of Oncology Volume 16 Number 8 Audio Journal of Oncology Volume 16 Number 8 15 Apr, 2008

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

  • Previous story Cancers of unknown primary site: biomarker profiling prompts paradigm shift in treatment decision-making
  • Next story Advanced, unresectable melanoma: survival rates at five years doubled with ipilimumab therapy
  • News

    • Mandeep Mehra MDCOVID-19 Co-Morbidity Risks Quantified from Three Continents SurveyMay 28, 2020
    • Ultrahypofractionated Radiation Just As Effective for Prostate CancerUltrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014
  • Related interviews

    • Ibrutinib: New Frontline Standard for Chronic…
    • Which New Combination for Metastatic Renal Cell Cancer?
    • Microbiome Diversity Key To Survival After…
    • Ribociclib Aids First-Line Endocrine Therapy in…
    • Polygenic Risk Scores Could Help Predict Second…
  • Home
  • Audio
  • Audio Journal of Oncology with Oncology Times News from the 2013 European Cancer Congress

© Copyright 2021 AudioMedica.com. Typegrid Theme by WPBandit.